Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD9 | Q9H8M2 | 17/20 | 0.58 |
| ▸ | BRD7 | Q9NPI1 | 3/20 | 0.58 |
| ▸ | TAF1 | P21675 | 2/20 | 0.58 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.58 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.58 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.58 |
| ▸ | CECR2 | Q9BXF3 | 2/20 | 0.58 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.58 |
| ▸ | BPTF | Q12830 | 1/20 | 0.58 |
| ▸ | TAF1L | Q8IZX4 | 1/20 | 0.58 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.58 |
| ▸ | ATAD2B | Q9ULI0 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | VHL | P40337 | 1/20 | 0.45 |
| ▸ | ELOC | Q15369 | 1/20 | 0.45 |
| ▸ | ELOB | Q15370 | 1/20 | 0.45 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33532942 | 0.97 | BRD9 (0.54) | BRD9BRD7TAF1TGFBR1ACVR1 | |
| SCHEMBL23123552 | 0.93 | BRD9 (0.54) | BRD9BRD7TAF1TGFBR1ACVR1 | |
| SCHEMBL25933271 | 0.93 | BRD9 (0.54) | BRD9BRD7TAF1TGFBR1ACVR1 | |
| SCHEMBL30297128 | 0.93 | BRD9 (0.56) | BRD9BRD7TAF1TGFBR1ACVR1 | |
| SCHEMBL23122723 | 0.91 | BRD9 (0.54) | BRD9BRD7TAF1TGFBR1ACVR1 | |
| SCHEMBL30297135 | 0.91 | BRD9 (0.52) | BRD9BRD7TAF1TGFBR1ACVR1 | |
| SCHEMBL22291259 | 0.89 | BRD9 (0.55) | BRD9BRD7TAF1TGFBR1ACVR1 | |
| SCHEMBL25174756 | 0.89 | BRD9 (0.62) | BRD9BRD7TAF1TGFBR1ACVR1 | |
| SCHEMBL30297123 | 0.88 | BRD9 (0.48) | BRD9BRD7TAF1TGFBR1ACVR1 | |
| SCHEMBL25933364 | 0.88 | BRD9 (0.49) | BRD9BRD7TAF1TGFBR1ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008778-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12351579-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250084081-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | US | disclosed |
| US-12157735-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2024-12-03 | — | — | US | disclosed |
| US-12049464-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240051953-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | US | disclosed |
| US-20240002382-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-01-04 | — | — | US | disclosed |
| US-20230066136-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-03-02 | — | — | US | disclosed |
| US-11560381-B1 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-11560381-B1 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2023-01-24 | — | — | US | disclosed |
| EP-4114392-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 Therapeutics, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| US-11414416-B1 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2022-08-16 | — | — | US | disclosed |
| US-20220098194-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2022-03-31 | — | — | US | disclosed |
| EP-3917517-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| WO-2021178920-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2021-09-10 | — | — | WO | disclosed |
| WO-2020160198-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020160198-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098194-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | BRD9 1/4885BRD7 8/4885TAF1 895/4885 |
| US-20230066136-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | BRD9 290/4885BRD7 149/4885TAF1 293/4885 |
| US-20240002382-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | BRD9 290/4885BRD7 149/4885TAF1 293/4885 |
| US-11414416-B1 | Compounds and uses thereof | VHL, TFEB, BECN1 | BRD9 290/4885BRD7 149/4885TAF1 293/4885 |
| US-12157735-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | BRD9 1/4885BRD7 8/4885TAF1 895/4885 |
| US-12049464-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | BRD9 1/4885BRD7 8/4885TAF1 895/4885 |
| US-11560381-B1 | Compounds and uses thereof | VHL, TFEB, BECN1 | BRD9 290/4885BRD7 149/4885TAF1 293/4885 |
| US-20240051953-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | BRD9 1/4885BRD7 8/4885TAF1 895/4885 |
| US-20250084081-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | BRD9 1/4885BRD7 8/4885TAF1 895/4885 |
| US-20260008778-A1 | COMPOUNDS AND USES THEREOF | BRD9, BCL9L, BCL9 | BRD9 1/4885BRD7 12/4885TAF1 86/4885 |
| US-12351579-B2 | Compounds and uses thereof | VHL, TFEB, BECN1 | BRD9 290/4885BRD7 149/4885TAF1 293/4885 |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | BRD9 290/4885BRD7 149/4885TAF1 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.